

# PROGRAMME

LEIPZIG  
INTERVENTIONAL  
COURSE

L I N C



Tobias Steinke

Page 1/2

Monday, January 25, 2021

## MAIN ARENA 1

- 11:30 – 12:25**      **SYMPOSIUM: A new era for vascular access: evidence-based strategies for optimizing AV fistula creation and maintenance**  
supported by Medtronic  
*MODERATOR:*  
Andrew Holden  
*PANEL:*  
Alexandros Mallios  
Jeffrey Hull  
**Tobias Steinke**
- 11:30 – 11:35      Introduction  
Andrew Holden
- 11:35 – 11:40      Panel discussion
- 11:40 – 11:50      Endovascular or surgical AV access creation: which option for which patient?  
Alexandros Mallios
- 11:50 – 11:55      Panel discussion
- 11:55 – 12:05      Challenges in AV access maintenance: treating the cephalic arch  
Jeffrey Hull
- 12:05 – 12:10      Panel discussion
- 12:10 – 12:20      My AV access maintenance algorithm  
**Tobias Steinke**
- 12:20 – 12:25      Panel discussion and programme conclusions

We are asking all faculty members to strictly respect the given time limits.

# PROGRAMME

LEIPZIG  
INTERVENTIONAL  
COURSE

L I N C



Tobias Steinke

Page 2/2

Tuesday, January 26, 2021

## MAIN ARENA 1

- 11:45 – 12:10**      **Pioneering approaches and new data: focus on venous and AV-shunt treatment**  
*MODERATOR:*  
Marianne Brodmann  
Michael Lichtenberg  
*PANEL:*  
Robert Shahverdyan  
**Tobias Steinke**
- 11:45 – 11:50      FIRST TIME DATA RELEASE: The IN.PACT AV access trial: subset outcomes through 12 month  
Andrew Holden
- 11:50 – 11:55      The IN.PACT AV access trial – economic outcomes  
Robert Lookstein
- 11:55 – 12:00      VIVO clinical study: Zilver Vena stent – 12 month results  
Lawrence Hofmann
- 12:00 – 12:05      Data from the ABRE study: clinical patient presentations in iliofemoral venous outflow obstruction –  
aDVT, PTS, NIVL  
Erin Murphy
- 12:05 – 12:10      FIRST TIME DATA RELEASE: Retrospective comparison of surgical AV access fistula creation vs. pAVF  
creation  
Robert Shahverdyan

We are asking all faculty members to strictly respect the given time limits.